Literature DB >> 35233682

Cervical Cancer Screening by Refugee Category in a Refugee Health Primary Care Clinic in Calgary, Canada, 2011-2016.

Molly Whalen-Browne1,2, Rachel Talavlikar3,4, Garielle Brown5, Kerry McBrien3,6, Mei-Ling Wiedmeyer7, Eric Norrie6, Gabriel Fabreau6,5.   

Abstract

Newly arrived refugees and refugee claimants experience low cervical cancer screening (CCS) rates in Canada. We investigated CCS at a dedicated refugee clinic. We completed a retrospective cohort study among patients at the Mosaic Refugee Health Clinic in Calgary, Canada, between 2011 and 2016. We investigated CCS offers and completion by refugee category. We then used multivariable logistic regression to estimate the association of CCS screening and refugee category, accounting for sociodemographic and clinical factors. We included 812 refugees. Most were married (71%) and had limited English proficiency (57%). Overall, 88% and 77% of patients were offered and completed screening, respectively. Compared to government assisted refugees, privately sponsored refugees completed CCS more often (OR 1.60, 95% CI [1.02-2.49]). A dedicated refugee clinic may provide effective CCS to newly arrived refugees irrespective of refugee category, insurance status or other barriers.
© 2022. The Author(s).

Entities:  

Keywords:  Cervical cancer; Primary care; Refugee health; Screening

Year:  2022        PMID: 35233682     DOI: 10.1007/s10903-022-01345-5

Source DB:  PubMed          Journal:  J Immigr Minor Health        ISSN: 1557-1912


  2 in total

1.  Rate of cervical cancer screening associated with immigration status and number of years since immigration in Ontario, Canada.

Authors:  Amole Khadilkar; Yue Chen
Journal:  J Immigr Minor Health       Date:  2013-04

2.  Knowledge of Healthcare Coverage for Refugee Claimants: Results from a Survey of Health Service Providers in Montreal.

Authors:  Mónica Ruiz-Casares; Janet Cleveland; Youssef Oulhote; Catherine Dunkley-Hickin; Cécile Rousseau
Journal:  PLoS One       Date:  2016-01-20       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.